Audentes Therapeutics announces dosing of first patient in ASPIRO for the treatment of X-Linked Myotubular Myopathy

Preliminary data from ASPIRO expected to be available in the fourth quarter of 2017
Audentes Therapeutics, abiotechnology company focused on developing and commercializing gene therapy products for patients  living with serious, life-threatening  rare diseases, today announced it has commenced dosing of patients in ASPIRO, a Phase 1/2 clinical trial of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM). ASPIRO is a multicenter, multinational, open-label, ascending dose study to evaluate the  safety and preliminary efficacy of AT132 in approximately twelve XLMTM patients less than five years of age. Preliminary data from ASPIRO is expected to be available in the fourth quarter of 2017.

Audentes is developing AT132 in collaboration with Genethon.